FLT3 and acute myeloid leukemia: It has received regulatory approval for use in patients exhibiting FLT3-mutated AML, specifically those with disease that has recurred or is non-responsive to prior treatments, and it has demonstrated good efficacy and tolerability in clinical trials (Yuan et al., 2022).